Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XCUR...above $2...🥳
What is the point of your post?🥳
XCUR...adding the dip at $2.01...🥳
XCUR...$2.41s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 355
Wednesday, August 28, 2024 11:35:48 AM
Post#
356
of 356
XCUR...$2.29s clearing here...🥳off my $2.11 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 652495
Wednesday, August 28, 2024 11:23:14 AM
Post#
655523
of 655531
XCUR...$2.11... Post Split...CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28, 2024 under the new CUSIP number 30205M 309. Exicure’s common stock will continue to trade on the NASDAQ Capital Market under the symbol “XCUR”. The Reverse Stock Split is an effort to regain compliance with Nasdaq’s listing rules.
The Reverse Stock Split was approved by the Company’s stockholders at its Special Meeting of Stockholders held on August 20, 2024, to be effected by the Company’s Board of Directors within approved parameters. The Company’s Board of Directors approved the Reverse Stock Split at a ratio of 1-for-5 on August 20, 2024.
XCUR...$2.29s clearing here...🥳off my $2.11 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 652495
Wednesday, August 28, 2024 11:23:14 AM
Post#
655523
of 655531
XCUR...$2.11... Post Split...CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28, 2024 under the new CUSIP number 30205M 309. Exicure’s common stock will continue to trade on the NASDAQ Capital Market under the symbol “XCUR”. The Reverse Stock Split is an effort to regain compliance with Nasdaq’s listing rules.
The Reverse Stock Split was approved by the Company’s stockholders at its Special Meeting of Stockholders held on August 20, 2024, to be effected by the Company’s Board of Directors within approved parameters. The Company’s Board of Directors approved the Reverse Stock Split at a ratio of 1-for-5 on August 20, 2024.
XCUR...$2.11... Post Split...CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28, 2024 under the new CUSIP number 30205M 309. Exicure’s common stock will continue to trade on the NASDAQ Capital Market under the symbol “XCUR”. The Reverse Stock Split is an effort to regain compliance with Nasdaq’s listing rules.
The Reverse Stock Split was approved by the Company’s stockholders at its Special Meeting of Stockholders held on August 20, 2024, to be effected by the Company’s Board of Directors within approved parameters. The Company’s Board of Directors approved the Reverse Stock Split at a ratio of 1-for-5 on August 20, 2024.
Hey xcur now you seen what happen today right? You reverse this prior and now we only are at 8 million OS share or there-a-bout and you are pulling another R/S!!!!!!! Many shareholder won't even lift a finger to vote and that sends a message to management.
XCUR...7037on the dip...🥳...CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on July 31, 2024, the Company received formal notice that the Nasdaq Hearings Panel (“Panel”) has determined to continue the Company’s listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by September 16, 2024. The Company is diligently working to timely satisfy the terms of the Panel’s decision and to ensure the Company’s continued listing on Nasdaq.
XCUR...92s clearing here...🥳
georgie18
Member Level
Re: None
Friday, August 02, 2024 9:24:48 AM
Post#
350
of 350
XCUR...79...strong volume...🥳
PUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUMP AND DUUUUUUUUUUUUUUUUUUUUUUUUUUUUUMP
NO MORE FOLKS
Think twice another reverse split is coming next month. Unreal!!!
Thank you. I'm going to stay on
the sidelines with this. Slipping into the OTC is not what I was looking for. Thanks again.
You can access the company but since they haven't updated security certificates you just need to enter the company from previous links you might access over the internet. As for XCUR? it seems on June 13th if the company does not get a blessing to extend platform this will fall back into the OTC market place. I'm not even going to check to see why the massive share traded last week but believe that was all about raising money however? I'm shaking my head as the leading investment corporate entity in S. Korea has plenty of dollars so my guess is either they didn't fully understand messing with XCUR, A deal collapse or the South Korean entity is still not ready to jump into this public USA trading just yet.
* just push through the expired cert and you will see you can still access the site.
Error message trying to view XCUR's website.
I get a warning message from Google when I click on it. Anyone else have that problem?
And @VHAI is noted, Sir --- THANKS!!
SOUNDS GOOD, THANKS********CHECK OUT VHAI****IPOed in JAN FEB***INSIDER BOUGHT AT $4 SOME CHANGE.
XCUR: Hey, Capt. TIM!! (As I said to 'FinalCD' earlier this moring, it's a real puzzle here for any kind of price increase. But ain't that the same for so many other soaring stocks?? Heck, what's behind the @STSS monster run --- and the only 'news' they had was a 'hold-to-sell' rating by some Wall Street guru. Nevertheless, if you are still pondering an XCUR grab, then be sure to WAIT until at least 11:00 a.m. NEW YORK time before you jump.)
"Howdy, Captain TIM!! I hope you had a great MAMMARY DAY weekend, Homeboy!!"
//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
SO BUY XCUR OR DON'T BUY XCUR***** WHAT IS YOUR TAKE ON THIS MY FRIEND
XCUR: Strange indeed; since had a 5-23-24 NASDAQ "Delisting" warning, & a ZERO revs. & other bad financials shortly before the "Delisting" routine. (But then, aren't DELISTING & LOW PRICE warnings 'trending' of late for a nice big soaring PRICE????)
XCUR WHY IS THIS TURD MOVING
OH I FORGOT IT DOESNT NEED A VALID REASON IN 2024
SMH
WELL? will XCUR become a company that deals with super large 3D advertising digital screens? (you will not need 3D glasses with this technology) or how about becoming a USA distribution hub either involving manufacturing or even if the hub might be just for marketing South Korea's 3D products? Something needs to give way soon.
Like I said XCUR isn't Exicure anymore and with us not actually doing any real development plus of course these guys haven't a clue, at the value of those patents. The players/institutional investments will be playing in Bluejay however you might hope that Bluejay might reverse merger but believe that won't happen.
One reason we won't see what we want in share price is because Exicure isn't Exicure any more. Sure our past management screwed us but these new kids on the block, from Korea had no clue about doing anything within the develop anything meaning their interest (seemed) to be more on having a public trading entity. Proof of the pudding is that they had no idea about the contract development between Exicure and NWU.
We lost massively in all out institutional investments and now are struggling to stay in the NASDAQ household in-which in several more months we most likely will kiss the OTC.
We are just a company trying to give out our valuable patents but just read the latest press release they haven't a clue of the value nor the work that went into all this in past years. So all we will get is crumbs. Now even the company we just made the tiny deal with will be at least 2 - 3 years in developing the studies, mixes and potential pre clinical.
In other words for us who stay for then RS may not but hop and poke with time. As for the traders timing might be bad.
Now the S Korean big dog - money man is successful but I'm not sure about the guy's presently holding offices. Is it possible the company will be more of a business hub between the US and SK?
XCUR: Suddenly appearing upon, and movin' UP, this list --- out of nowhere!!
https://www.barchart.com/investing-ideas/penny-stocks?orderBy=percentChange5d&orderDir=desc
XCUR: Suddenly appearing upon, and movin' UP, this list --- out of nowhere!!
https://www.barchart.com/investing-ideas/penny-stocks?orderBy=percentChange5d&orderDir=desc
XCUR: Here we Gooooooooooo!!! (Maybe there IS a God!!!!) Don't like my Atheistic jokes, then SCREW-YAH!!! Face MECCA, or put your hands on your "WAILING BUTTS"!!!)
If it breaks .80 again...it may grow legs...under 9 million OS?
Thanks the robots gapped it up too high too quick, so didnt have a big trading range
whats your thoughts on the action and the XCUR news
The system can design drug plan(s) digitally and pursue 3 different tasks at the same time, also turning on and off cells and delivering by way of scavenger receptors, delivering less drug, raising efficiency and causing less damage to the liver/patients.
No doubt we needed something but weak statements that lack real information...it appears this effort might be to hold/move share price that may very well work against the company. Being invested in Exicure for around 4 years it appears the other company was in great need of a new way/delivery system plus the 3D digital system which was why I invested in XCUR years ago.
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO--(BUSINESS WIRE)-- Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
Under the terms of the agreement, Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of this Agreement. Exicure will also be entitled to modest royalties on future net sales on all licensed technology by Bluejay during the term of the licensed patents. Exicure will be responsible for, and make all decisions concerning, the preparation, filing, prosecution, and maintenance for each patent and patent application included within the licensed patents.
"Our partnership with Bluejay continues the development of cavrotolimod," said Paul Kang, Chief Executive Officer of Exicure. "Exicure has spent considerable resources to discover and develop cavrotolimod. While historically, we focused on oncology, Bluejay’s commitment and expertise in developing cavrotolimod for potential treatment of hepatitis makes them an ideal partner to expand the use case of cavrotolimod," added Mr. Kang.
About Exicure
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.
Forward-Looking Statements
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
Paul Kang will reverse a private company into XCUR but in the meantime he has paid directors the typical $20k so that he can maintain listing and also push the the SEC tolerances to the limit before actually being delisted. I believe we will not be involved in any of the past operations that we were and I believe from all the reading I have done. I keep shaking my head on what business we will do and feel that Mr. Kang is using Exicure as a shell company. I had hope that we would become some type of business hub focused on renewable energy I mean 30k sq ft isn't bad for starters plus half of that is leased office staff is already and believe it to be a S. Korean entity.
Subslover....we are at 55 days of 60 for management to send a plan to the SEC to enable XCUR to remain on the Nasdaq.
XCUR........................................https://stockcharts.com/h-sc/ui?s=XCUR&p=W&b=5&g=0&id=p86431144783
Short manipulators out in force premarket trying to keep their azzas from getting squeezed over a buck, like they were getting in thevafter hours,
Exicure Granted Broad U.S. Patent #11866700 Today For "Liposomal Nucleic Acid Constructs Presenting Antisense Oligonucleotides For Knockdown Of Interleukin 17 Mrna (For Inflammation From Cancer, Obesity, Diabetes, Alzheimer's)"